CFMG & Wellpath in California — a documentary investigation · Article 023 of 100 · Series 3 — Physician executives, ownership and succession

Judd Bazzel: From Correct Care Clinical Executive to CFMG President

Published

20 September 2026, 6:00 PM PT

Content last changed

20 September 2026, 6:00 PM PT

Public-evidence cutoff

20 September 2026, 6:00 PM PT

Sources checked

20 September 2026, 6:00 PM PT

Record through

20 September 2026, 6:00 PM PT

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

Judd Bazzel: From Correct Care Clinical Executive to CFMG President is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

The governing question is narrow: What does Bazzel's career reveal about physician-executive portability across the enterprise? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

Wellpath now publicly describes CFMG as a physician-owned affiliate#

In March 2026, Wellpath announced a new California-focused operating division called Local Government-California . In the same release, Wellpath called CFMG a Wellpath affiliate and stated in a footnote that CFMG is a professional corporation owned by licensed physicians and affiliated with Wellpath’s management-services organization. Wellpath also described the use of enterprise data infrastructure across its affiliates. Source: Wellpath, Mar. 13, 2026

That is the company’s current public description of the relationship. It is useful evidence of how Wellpath describes the architecture; it is not independent proof of the identity of CFMG’s individual shareholders or of how professional authority functions in every decision.

Rule 7.1 “corporate parent” anomaly#

Several 2023–2024 Northern District dockets show Wellpath LLC identifying CFMG as a “Corporate Parent.” Other filings identify CFMG merely as an “Other Affiliate,” and a 2026 CFMG disclosure reciprocally identifies Wellpath LLC as an “Other Affiliate.” These labels also conflict with the bankruptcy ownership chart and current physician-ownership description.

This is a high-priority reconciliation issue. It is not yet proof that CFMG owned Wellpath LLC, and it should not be dismissed as a typo without the actual disclosure forms.

Raymond herr — the longest documented post-founder president#

The public record supports a strong chronology for Herr:

• April 2015 — identified in Shepherd evidence as CFMG Chief Medical Officer and President.

• March 2017 — signs CFMG collective-bargaining agreement as President.

• December 2017 — signs Stanislaus contract as President.

• 2018 — identified by Alameda County as CFMG Chief Medical Officer and President.

• September 2018 — CDPH lists him as President and Chief Medical Officer.

• 2018 — signs Fresno CFMG agreement as President.

• 2020 — appears on Placer agreement as CFMG President.

• September 8, 2021 — signs Monterey Amendment No. 2 as CFMG President.

This is a substantial run of formal corporate/contractual evidence.

It gives Herr an unusually important place in the governance history because his tenure spans:

• the mature H.I.G./CMGC period;

• the 2018 CCS–CMGC combination;

• the creation of the Wellpath brand;

• the 2019 MSA assignment to Wellpath LLC.

The key unanswered question is:

What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

September 2021 provides the first clear CFMG corporate role for bazzel in the current source set#

Monterey Amendment No. 2, executed September 8, 2021, shows:

• Raymond Herr, M.D. — President

• Judd Bazzel — Treasurer

This is unusually useful because two corporate offices appear on the same executed CFMG instrument.

It establishes that by September 2021:

• Herr remained CFMG president;

• Bazzel already held a CFMG corporate-finance office.

This is the cleanest currently verified transition point between the Herr era and Bazzel era.

Richard medrano is a particularly important cross-role figure#

Richard Medrano, M.D., emerges as a CFMG corporate officer while simultaneously holding an operational role inside Wellpath.

Public Wellpath proposal materials identify Medrano as a Regional Medical Director and state that he joined Wellpath in 2017.

A 2024 county proposal says he oversees medical services in the West and Southwest region.

CFMG county contracts, meanwhile, identify him as:

• Vice President;

• Vice President & Secretary;

• Corporate Secretary;

• later Secretary.

Thus Medrano occupies both:

• a CFMG corporate-governance role;

• and a Wellpath regional clinical-management role.

This does not automatically undermine CFMG independence.

A physician can serve two affiliated entities.

But dual roles matter because the same physician may be expected to:

• act as a fiduciary/officer of CFMG;

• implement Wellpath regional clinical strategy;

• participate in decisions where the PC and MSO interests differ.

The high-value evidence is therefore conflict handling and actual decision records, not the mere fact of dual titles.

2022–2024 — BAZZEL BECOMES THE CONSISTENT CONTRACT-SIGNING PRESIDENT#

The public county record after the transition becomes much more consistent.

Examples include:

• Humboldt 2022 — Bazzel, President.

• Monterey December 2022 — Bazzel, President.

• Fresno 2023 — Bazzel, President.

• Sonoma labor agreement signed in 2023 — Bazzel, President.

• Solano 2024 — Bazzel, President.

• Tuolumne 2024 — Bazzel, President.

This pattern establishes Bazzel as the principal public CFMG corporate officer before bankruptcy.

The legal question then becomes:

Was he also the Company Designee under the MSA, and what shareholder/director authority stood behind his actions?

That cannot be answered from title alone.

Scott kennedy enters the public CFMG corporate record#

Scott Herbert Kennedy, M.D., appears in the post-Herr CFMG structure.

An El Dorado County contract record from late 2022 identifies:

• Bazzel as President;

• Kennedy as Vice President/Treasurer.

By January 2025, the California Secretary of State identifies Kennedy as:

• Chief Financial Officer

• Director

He therefore clearly held formal CFMG corporate authority by 2025.

However, unlike Bazzel and Medrano, the present public source set does not yet permit the investigation to reconstruct Kennedy's pre-CFMG Wellpath/CCS role with equal confidence.

That gap should remain explicit.

the record should not infer a particular Wellpath executive history simply because Kennedy's CFMG address and email infrastructure are associated with the Wellpath enterprise.

The public governance record actually contains strong defense evidence#

An objective CPOM record must recognize that the governance history contains evidence supporting the legality of the structure.

• CFMG consistently existed as a separate California professional corporation.

• Physician presidents signed major county agreements.

• Current directors are physicians.

• CFMG remained a nondebtor PC during Wellpath bankruptcy.

• Post-bankruptcy contracts continue to be signed in CFMG's name.

• Wellpath publicly says CFMG is physician-owned.

• Hallman publicly said there was no ownership overlap.

• County contracts invoke ordinary corporate-signature formalities.

• The current Secretary of State filing names physician directors rather than Wellpath's nonphysician executive board.

These facts weigh against a simplistic "shell company" narrative.

Corporate disclosures — affiliate/parent labels as source-tracing material#

Several federal cases include corporate-disclosure entries describing CFMG and Wellpath through “affiliate,” “other affiliate,” or more expansive relationship labels.

These are useful for establishing that a disclosed corporate relationship existed or was represented.

They are poor substitutes for:

• stock ledgers;

• shareholder agreements;

• capitalization tables;

• governance instruments;

• or the MSA.

A Rule 7.1 label should therefore be coded:

relationship representation — authenticate underlying corporate basis.

Exact disclosure language is reproduced here only with:

• case;

• ECF number;

• filing date;

• filing party;

• signatory;

• and surrounding form context.

II. Structural and Historical Context#

Shareholder-succession event table to build once the agreement is found#

For every historical owner transfer:

The likely historical periods needing reconstruction are:

• founder era;

• 2012–2013 H.I.G. transaction;

• Fithian/Herr transition;

• 2018 CCS–CMGC combination;

• Herr/Bazzel transition;

• 2024 bankruptcy;

• 2025 lender emergence;

• 2026 Local Government–California restructuring.

The chronology should remain blank where ownership is unproven rather than inferring ownership from officer titles.

III. The Control and Governance Analysis#

Why these documents matter now#

California Attorney General enforcement in 2026 has focused directly on structures in which an MSO or private-equity-backed enterprise can:

• replace a physician shareholder;

• control who succeeds the shareholder;

• make physician ownership dependent on continued use of the MSO;

• prevent the physician practice from replacing the MSO without risking ownership.

That is precisely why the CFMG stock-transfer documents can no longer be treated as incidental corporate paperwork.

The decisive questions are:

• Who could become a CFMG shareholder?

• Who nominated or approved successors?

• Could Wellpath veto a proposed physician shareholder?

• Could Wellpath require replacement of a physician shareholder?

• What happened upon death, disability, loss of licensure, resignation, retirement, termination, or bankruptcy?

• Was any stock held in escrow?

• Did any proxy, option, nominee arrangement, succession list, or power of attorney exist?

• Who fixed the share-purchase price?

• Who funded the purchase?

• Did Wellpath or an affiliate possess a security interest tied to the shares?

• Could a physician owner remain owner after terminating the MSA?

• Could the physician owner sell to another qualified physician without Wellpath approval?

Until these instruments are obtained, no confident conclusion should be made about ultimate ownership succession.

The company-designee mechanism can concentrate CFMG corporate authority#

Section 1.4 of the MSA provides that when CFMG approval, consent, direction, or action is required, the action of the person designated as CFMG's Chief Executive Officer under its bylaws—the Company Designee —constitutes action of CFMG unless otherwise specified.

The management company may assume that required internal CFMG consents and approvals have been obtained.

This can be a commercially efficient agency mechanism.

But it can also become an evidentiary bottleneck.

If extensive CFMG corporate authority passed through one physician officer, the critical questions become:

• who held the Company Designee role each year;

• whether that person was a shareholder;

• whether that person held roles on the Wellpath/MSO side;

• what independent information the designee reviewed;

• whether board/shareholder deliberation occurred;

• whether the designee ever rejected management recommendations.

A structure can be formally physician-controlled while still concentrating all practical PC approval in one physician officer.

That is not automatically unlawful.

It does mean the independence of that office is central.

Reconstructing shareholder identity YEAR BY YEAR#

County contracts provide some direct corporate-signature evidence.

For example, a 2023 Placer County contract was executed for CFMG by:

• J. Bazzel as President;

• R. Medrano, M.D. as Secretary.

The document expressly invokes California Corporations Code section 313 execution formalities.

This supports the existence of functioning CFMG corporate officers.

The complete governance reconstruction should identify by year:

• shareholders;

• directors;

• president/CEO;

• secretary;

• CFO/treasurer;

• Company Designee;

• medical directors;

• any overlapping Wellpath positions.

The goal is not to imply wrongdoing from overlapping roles.

It is to identify which people actually carried the physician-corporation's legal authority.

The same governance record also justifies deeper control review#

Other facts justify investigation rather than a presumption of independence:

• The original MSA was signed by the same CEO on both sides.

• H.I.G. was included in the MSA notice architecture from inception.

• The manager may attend and participate in CFMG governance meetings.

• Company action can be concentrated through a single Company Designee.

• The 2019 assignment transferred stock-transfer restriction agreements into the Wellpath management structure.

• Bazzel came from the pre-merger CCS executive structure.

• Medrano simultaneously holds Wellpath regional medical and CFMG corporate roles.

• CFMG's principal office migrated from California to Wellpath's Tennessee corporate infrastructure.

• Current officers/directors use the same Tennessee administrative locus.

• Current shareholders remain undisclosed in the public evidence.

• The actual stock-succession rules remain missing.

Again, those facts do not establish illegality.

They identify the precise governance records needed to answer the question.

THE MARCH 2026 LOCAL GOVERNMENT–CALIFORNIA REORGANIZATION CREATES A SECOND GOVERNANCE STRESS TEST#

On March 13, 2026, Wellpath announced creation of a new operating division:

Local Government–California

and appointed Jessica Mazlum as Division President.

Wellpath expressly described CFMG as:

• a Wellpath affiliate;

• a professional corporation;

• owned by licensed physicians;

• affiliated with Wellpath’s management-services organization.

Primary source:

https://wellpathcare.com/2026/03/13/wellpath-announces-creation-of-a-new-operating-division-in-california-appoints-new-highly-experienced-leader/

Wellpath also said the California operation would leverage the company’s enterprise data infrastructure.

This creates a new post-bankruptcy governance question:

What CFMG corporate action authorized the role of the Local Government–California division in the operations supporting CFMG’s California contracts?

Possible answers include:

• no CFMG approval was needed because the division was merely an internal MSO reorganization;

• CFMG approved a delegation;

• the existing MSA already allowed the reorganization;

• or amendments/delegation matrices were executed.

The public announcement does not answer that.

Again, the issue is not whether a nonphysician can lead an MSO division. A nonphysician can.

The question is where her authority ends and CFMG physician authority begins.

The strongest current documentary reconstruction is that the CFMG management relationship did not require a new publicly filed post-bankruptcy assignment to move from the H.I.G.-era enterprise into reorganized Wellpath.

The more likely mechanism is simpler:

Wellpath LLC was already the manager under the January 1, 2019 assignment; it entered Chapter 11 as the contracting debtor; the CFMG MSA was still being described by Wellpath as operative during bankruptcy; the final Plan deemed all executory contracts assumed unless specifically rejected or otherwise excepted; no California Forensic Medical Group / CFMG MSA entry has been located in the reviewed rejection notices or final rejection schedule; the Confirmation Order made those assumptions effective without further court order; and the assumed contract re-vested in the applicable contracting Post-Restructuring Debtor.

That chain makes deemed assumption by Wellpath LLC on the May 9, 2025 Effective Date the best-supported explanation for continuity of the CFMG MSA.

This conclusion rests on five independent documentary points. First, the January 1, 2019 Assignment expressly made Wellpath LLC the “Manager” under the CFMG MSA. Second, as late as February 11, 2025, Wellpath’s own bankruptcy filing described CFMG as a professional corporation to which the Debtors provided managerial services pursuant to the January 2019 CFMG MSA . Third, Article V of the confirmed Plan provides that, on the Effective Date, all executory contracts are deemed assumed by the applicable Post-Restructuring Debtor unless they fall within stated exceptions. Fourth, the final Rejected Executory Contracts Schedule filed April 29, 2025 affirmatively rejects another professional-corporation relationship— Grand Prairie Healthcare PC —while no CFMG / California Forensic Medical Group entry has been located in the searchable final schedule. Fifth, a 2026 Sonoma County professional-services agreement again expressly identifies Wellpath LLC as the Management Services Organization providing administrative services to CFMG .

The conclusion requires one important qualification. The precise Docket 194 schedule row and proposed cure amount for the CFMG MSA have not yet been located in the searchable public corpus, and this investigation has not located any private post-emergence amendment or CFMG board ratification. Accordingly, the statement that the CFMG MSA was deemed assumed is a high-confidence documentary/legal inference , not a substitute for obtaining the exact contract register and cure schedule.

"PATIENT SAFETY" IS WHERE ORDINARY HR AND PHYSICIAN GOVERNANCE MEET#

Where a termination or separation communication invokes clinical safety rather than paperwork alone, the decision stops being an ordinary human-resources matter. A statement that a clinician’s return could endanger the clinician or patients is a clinical judgment in substance, whatever its administrative form — and clinical judgment inside a California professional corporation is reserved to the professional entity, not to the management organization that may administer the paperwork around it.

That is why the decision chain matters more than the wording. The question is not whether an administrator may communicate such a decision; plainly one may. The question is whether the professional judgment underlying it was made by the professional corporation before implementation, or supplied afterwards to explain an act already taken. The proper-channel test and the first-decision test answer different halves of that question: the first asks whether the decision travelled through the body actually holding the authority, the second asks whether professional review preceded or followed the operative act.

Neither half can be answered from a communication alone. A letter establishes that a reason was given at a time. It does not establish who held the decision right, what any professional body reviewed, or whether that review was substantive rather than ratificatory. The records that would answer it — committee minutes, written consents, the contemporaneous decision file, the referral path for a fitness-for-duty question — are not in the public record for this project, and this investigation does not infer their contents from the fact that a decision was communicated.

California's Medical Board guidance states that Business and Professions Code section 2400 is intended to prevent unlicensed persons from interfering with or influencing physician professional judgment.

The Board identifies physician-controlled decisions to include:

• diagnostic testing;

• referrals;

• ultimate patient care;

• and how many patients a physician must see or how many hours a physician must work.

It also identifies management decisions that should remain under licensed-physician control when they control medical practice, including:

• selection, hiring, and firing as it relates to clinical competency or proficiency .

The key qualification is the phrase as it relates to clinical competency or proficiency .

Not every termination of a physician is a medical decision.

A professional corporation can use ordinary HR administrators to investigate attendance, payroll, interpersonal conduct, policy compliance, or other nonclinical matters.

An MSO can provide lawful administrative assistance.

But if the operative reason for continued exclusion or termination is:

this physician cannot safely treat patients,

then the investigation must determine whether a licensed CFMG physician independently made or approved that professional judgment.

That is the strongest CPOM-relevant framing currently supported by the record.

It avoids the overbroad proposition that every physician-HR decision must personally be performed by a physician.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.

Current evidence favoring structural independence#

The strongest evidence favoring genuine structural independence includes:

• CFMG remained a separate nondebtor professional corporation during Wellpath bankruptcy.

• Wellpath's own board co-chair publicly stated there was no ownership overlap.

• County materials describe CFMG as a separate physician-owned entity.

• CFMG signs county contracts through physician corporate officers.

• The MSA expressly preserves professional judgment.

• CFMG possesses contractual rights to terminate for material manager breach.

• Management's governance representative is expressly nonvoting.

• CFMG is the covered entity under HIPAA while management is the business associate.

• CFMG appears to own/hold the professional contracts with California counties.

• The MSA contemplates CFMG board evaluation of management performance and bonus determinations.

These facts are meaningful and must remain in the final analysis.

DHEERAJ TARANATH is distinct from THE VERIFIED CFMG BOARD#

Dr. Dheeraj Taranath is highly relevant to CFMG operations, but the current evidence does not establish him as a CFMG shareholder, director, or officer.

Wellpath's current leadership page identifies him as:

Chief Clinical Officer, Wellpath

The Wellpath bankruptcy plan likewise listed him among the officers of reorganized Wellpath as Chief Clinical Officer.

County materials in 2026 identify him as a Wellpath chief medical/clinical executive.

He has also communicated on CFMG-related matters.

But those facts do not put him on CFMG's board.

This distinction is important because loose shorthand of the form "physician shareholders and leadership" is easy to apply to any senior clinician associated with the enterprise, including Taranath.

For public publication, that shorthand must not become a factual assertion of share ownership.

The correct description is:

Wellpath Chief Clinical Officer who has participated in CFMG-related clinical/organizational matters; no current public proof of CFMG share ownership or board office identified.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.

The documents that now matter most#

Tier One:

• Every stock-transfer restriction agreement referenced in the 2019 assignment.

• Current CFMG stock ledger.

• Current shareholder agreement.

• Shareholder succession agreements.

• Options, proxies, nominee agreements, powers of attorney.

• CFMG bylaws.

• Company Designee appointments.

• Full Deficit Funding Loan Agreement and amendments.

• UCC-1 financing statements and continuations/terminations.

• Current security agreements.

• Bank signature cards.

• ACH and treasury authorities.

• Deposit-account control agreements.

• 2012 Credit Agreement and successor/refinancing agreements.

• Every MSA amendment since 2012.

• Post-bankruptcy ratification/assumption documents.

• 2025–2026 CFMG board/shareholder minutes.

• Monthly management-company bonus resolutions.

• Management-fee/FMV analyses.

• Current New WPCC Parent capitalization and governance agreements.

Tier Two:

• Intercompany ledgers.

• CFMG general ledger.

• Wellpath management-fee invoices.

• Deficit-funding advance history.

• Insurance/claims agreements.

• IT/data exit provisions.

• county change-of-MSO approval provisions.

• employment/personnel transition restrictions.

• Local Government–California delegation matrix.

• documents showing whether CFMG considered alternative managers during bankruptcy.

CFMG Shareholders, Directors, Officers, Company Designees, Stock Succession, Cross-Roles, and the Search for the Missing Stock-Transfer Agreements#

the prior analysis establishes why ownership succession is the top unresolved structural issue.

the prior analysis should reconstruct:

• every identifiable CFMG shareholder;

• every president/CEO/secretary/CFO;

• every Company Designee;

• overlap with CMGC/Wellpath roles;

• corporate signature history;

• death/resignation/retirement succession events;

• public filings and county contracts;

• historical H.I.G./CMGC transaction representations;

• the most likely repositories for the missing stock agreements.

Only after that chain is reconstructed should the investigation draw any conclusion about who ultimately controlled CFMG ownership.

After six volumes, the most important remaining structural question is ownership.

This article produces a significant clarification:

The public record now permits a reasonably strong reconstruction of CFMG's corporate officers and directors over time, but it still does not identify the current CFMG shareholders or their percentages with sufficient reliability.

That distinction is critical.

A person can be:

• a physician;

• an officer;

• a director;

• a president;

• a chief executive officer;

• a Company Designee under the MSA;

• a medical director;

• a Wellpath executive;

• and even the person signing CFMG contracts

without necessarily being a shareholder.

Conversely, a shareholder may hold no public operating title.

Accordingly, officer succession cannot be treated as proof of stock succession .

The strongest current governance evidence is:

• the 2012 MSA;

• county contracts signed under California corporate formalities;

• California Secretary of State Statements of Information;

• federal litigation;

• labor agreements;

• the Wellpath bankruptcy;

• Wellpath public corporate materials.

Those records establish who held many formal offices.

They do not disclose the stock ledger.

The stock-transfer restriction agreements expressly referenced in the 2019 assignment therefore remain the single most important missing ownership source.

Edward o'bryan creates another important title interruption in 2021#

A December 2021 Humboldt County proposal submitted by Wellpath/CFMG identifies:

Edward O'Bryan, M.D., MBA, CPE — President of CFMG

The same proposal identifies Kip Hallman as President on the Wellpath side.

This is a strong documentary fact about how the bidder presented its leadership.

But it conflicts with:

• Raymond Herr signing Monterey as CFMG President in September 2021;

• Bazzel emerging as CFMG President by September 2022.

The public professional biographies of O'Bryan describe him as a senior Wellpath clinical executive during roughly 2020–2022.

Accordingly, the current evidence supports the following cautious formulation:

During the 2021–2022 transition period, at least one formal Wellpath/CFMG proposal identified Edward O'Bryan as CFMG President, while contemporaneous executed county contracts identify Herr and later Bazzel as President. The exact corporate duration and legal basis of O'Bryan's CFMG presidency requires corporate records.

This is precisely the kind of discrepancy the record is designed to preserve.

The current shareholder question remains unanswered#

This is perhaps the most important conclusion of the prior analysis.

The January and November 2025 California Statements of Information tell us:

• officers;

• directors;

• addresses.

They do not tell us:

• shareholders;

• share percentages;

• stock certificates;

• beneficial ownership;

• succession rights.

Wellpath has publicly described CFMG as physician-owned.

Kip Hallman publicly described it as owned primarily by a group of physicians and said there was no ownership overlap with Wellpath.

Those are meaningful corporate statements.

But the actual ownership schedule has not yet been obtained.

Accordingly, the record should not publish:

• "Bazzel owns CFMG";

• "Bazzel, Medrano and Kennedy are the shareholders";

• "Taranath is a CFMG shareholder";

• "Wellpath owns CFMG";

• "H.I.G. owns CFMG stock."

None of those propositions is currently established by sufficiently reliable primary evidence.

The stock-transfer restrictions could explain the succession pattern — but the documents are missing#

The 2019 assignment's express reference to "relevant stock transfer restriction agreements" becomes more important when placed beside the officer succession.

At least three major physician-leadership transitions occurred:

• Fithian era → Herr era;

• Herr era → transitional O'Bryan/Bazzel period;

• Bazzel era → current three-director board.

The unresolved question is whether any of these officer transitions coincided with stock succession.

Questions:

• Did Fithian sell or transfer shares?

• Did Herr acquire shares?

• Did Bazzel acquire shares?

• Were Medrano or Kennedy issued shares?

• Was a single physician shareholder replaced while board offices changed around that person?

• Did Wellpath or its predecessor have contractual approval over the transferee?

• Was stock held subject to a transfer restriction favoring the MSO?

• Did a physician's employment status affect ownership?

Those questions cannot be answered from public officer titles.

The stock documents are necessary.

THE WELLPath CFMG / CFMG HOLDINGS ENTITY MAY HELP EXPLAIN HISTORICAL CONFUSION ABOUT "PARENT" STATUS#

The discovery that Wellpath CFMG, Inc. was formerly CFMG Holdings Corp. provides a new interpretive clue.

Federal and other records have at times used descriptions such as:

• CFMG parent;

• CFMG subsidiary;

• CFMG affiliate;

• CMGC parent.

Some of those descriptions may reflect genuine relationships.

Some may reflect shorthand.

And some may be complicated by the coexistence of:

• the professional corporation;

• CFMG Holdings Corp.;

• Correctional Medical Group Companies;

• Wellpath CFMG, Inc.;

• Wellpath Management.

This is especially important for the unresolved Rule 7.1 corporate-disclosure anomaly identified in the prior analysis.

The correct next step is not to infer that the disclosures are wrong.

It is to retrieve the exact filed forms and identify which legal CFMG entity the disclosure actually names .

The naming collision is a plausible source of confusion, but that remains an inference until the filings are reviewed.

The bankruptcy motion directly confirms stock-transfer agreements#

Before the bankruptcy review, the strongest evidence of CFMG stock-transfer restrictions came from the January 2019 assignment, which expressly transferred related instruments including “relevant stock transfer restriction agreements.”

Docket No. 15 materially strengthens that evidence at the enterprise level.

The Debtors disclosed that, in addition to PC Management Services Agreements, they and certain physician owners were parties to:

Stock Transfer Agreements

that:

• restrict transfer of a physician owner’s stock;

• facilitate a streamlined transition of ownership;

• promote compliance with state professional-entity requirements;

• address transfer events such as death and disability;

• promote continuity of care;

• and promote the continuation of administrative services by the Debtors .

The Debtors further stated:

Under the Stock Transfer Agreements, the Debtors have authority to ensure that the Professional Corporation is duly licensed and qualified.

This is one of the most important new findings in the entire record.

It establishes that stock-transfer arrangements were not merely passive restrictions designed to prevent transfer to an unlicensed person.

At least at the enterprise level, the Debtors themselves described the agreements as tools tied to:

• ownership transition;

• licensing continuity;

• and continuation of the Debtors’ management relationship.

That is precisely the type of contractual architecture California’s 2026 Art Center and Carbon Health enforcement developments make significant.

But a crucial limitation remains.

Docket No. 15 speaks generically about “certain PC Physicians.”

It does not publish the CFMG-specific Stock Transfer Agreement or state that every provision described applies identically to CFMG.

The CFMG connection is nevertheless stronger than a generic inference because the 2019 CFMG assignment independently confirms that relevant stock-transfer restriction agreements existed in the CFMG relationship .

The two sources therefore fit together:

2019 CFMG Assignment: CFMG-related stock-transfer restrictions existed and were assigned into the Wellpath structure.

2024 PC Motion: Wellpath explains the purposes and functions of Stock Transfer Agreements in its friendly-PC model generally.

The remaining question is the exact CFMG text.

The missing CFMG board record should not be treated as evidence of absence#

Because CFMG was a nondebtor, its ordinary board minutes would normally remain private corporate records.

A bankruptcy court generally does not require every nondebtor counterparty to publish internal deliberations merely because its contract partner files Chapter 11.

Therefore:

No public CFMG board minutes found ≠ no CFMG board deliberation occurred.

But where the substantive question is physician independence, those records become the best direct evidence.

The public record should therefore say:

No publicly filed CFMG board record has yet been identified showing how its physicians evaluated the manager’s bankruptcy and ownership transition.

That is accurate and neutral.

Article v.f makes the missing stock agreements more, not less, important#

One might initially assume that confirmation rendered the stock-transfer issue irrelevant. The opposite is true.

If the MSA was broadly assumed together with related agreements and interests, then determining the exact scope of the CFMG-related instruments becomes even more important.

The 2019 Assignment expressly links the MSA, related/incidental instruments, and stock-transfer restriction agreements. The bankruptcy PC Motion separately describes stock-transfer agreements as part of the friendly-PC system and says they support continuity of Debtor administrative services. Article V.F then uses broad language about modifications, amendments, supplements, restatements, related agreements, options, rights, and interests.

The convergence of those documents means the CFMG-specific stock instrument should now be treated as a Plan-continuity document , not merely a historical ownership document.

The exact instrument could reveal whether ownership-succession control also crossed the May 9, 2025 restructuring boundary.

A reported physician decision does not, by itself, complete the decision chain#

A governance question can be posed publicly without any private record: if a future public filing, deposition or produced document shows physician participation in a specific personnel decision, that would be direct evidence of professional governance in operation. Until then the question stays open.

The same sequence applies to any public decision event through the same sequence used elsewhere in the series: origin → recommendation → authorized professional review → approval or veto → implementation . A later physician ratification is not the same as an originating decision; a management recommendation is not the same as final authority; and mere alignment does not reveal who would prevail under disagreement.

The highest-value evidence is a conflict-tested record showing that an authorized CFMG physician body could say no and that the enterprise was required to follow its decision—or the reverse. Until such a public record is available, private personnel material should remain a research lead rather than a published merits proposition.

Tier-one open evidence#

The highest-value missing items remain:

• CFMG-specific stock-transfer restriction / succession agreement.

• CFMG stock ledger and shareholder roster by year.

• CFMG bylaws and Company-Designee appointments.

• Proxy, option, stock-power, escrow, nominee, or power-of-attorney instruments.

• Docket 194 CFMG assumption/cure row and proposed cure amount.

• CFMG board/shareholder minutes from the bankruptcy and emergence period.

• Deficit Funding Loan Agreement.

• UCC/security-interest records.

• Cash/bank signature and treasury authorities.

• Monthly CFMG management-bonus resolutions.

• Smith ECF 156 and full financial-discovery record.

• Full Overfield Chapman termination file/approval chain.

• Utilization-management denial/appeal/override records.

• Current Local Government–California delegation matrix.

• Post-emergence MSA/stock-instrument amendments or reaffirmations.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 022 — Raymond Herr: The Physician Executive Who Bridges CFMG and the Enterprise

• Article 024 — Richard Medrano: One Physician, Two Institutional Roles

• Article 021 — Taylor Fithian and the Founder-Era Governance Baseline

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: What does Bazzel's career reveal about physician-executive portability across the enterprise? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are executive portability, physician officer, patient-safety role, and corporate governance. The source spine identified in the current public record is: CCS resume/proposals; Wellpath Patient Safety role; CFMG Treasurer→President; current contracts; clinical-form ownership. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for Judd Bazzel: From Correct Care Clinical Executive to CFMG President should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. Judd Bazzel: From Correct Care Clinical Executive to CFMG President is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

An executive's roles, sorted by a court#

The institutional roles this article traces sit inside entities that a federal court has now treated as legally distinct in the one setting where distinctness is most consequential. In Estate of Jeremiah Wright v. County of Stanislaus, E.D. Cal. No. 2:24-cv-02505, order of September 15, 2026, Wellpath LLC was dismissed as a discharged debtor, Wellpath Management, Inc. was not dismissed on the present pleadings, and CFMG remained as a nondebtor professional corporation.

For a physician executive who held office across those entities, the order illustrates why capacity matters. An act taken as an officer of the professional corporation and an identical act taken as an executive of the management organization now have different litigation consequences, because one entity has been discharged and the other has not. The court did not decide anything about this or any individual's authority; it decided which entities remained suable. But it makes concrete a distinction this article has drawn on paper — that the same person, acting through different institutional hats, engages different legal persons with different fates.

Sources and authorities#

1. Source: Wellpath, Mar. 13, 2026 wellpathcare.com — https://wellpathcare.com/2026/03/13/wellpath-announces-creation-of-a-new-operating-division-in-california-appoints-new-highly-experienced-leader/